# Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140

> **NCT02483078** · PHASE2,PHASE3 · COMPLETED · sponsor: **CytoDyn, Inc.** · enrollment: 52 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** PRO 140
- **DRUG:** Placebo
- **DRUG:** Optimized Background Regimen

## Key facts

- **NCT ID:** NCT02483078
- **Lead sponsor:** CytoDyn, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2018-02
- **Final completion:** 2018-07
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2022-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02483078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02483078, "Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02483078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*